Friday’s Top Options Alert: Bristol-Myers & Mead Johnson (BMY, MJN)

Photo of Douglas A. McIntyre
By Douglas A. McIntyre Updated Published
This post may contain links from our sponsors and affiliates, and Flywheel Publishing may receive compensation for actions taken through them.

Bristol-Myers Squibb Co. (NYSE: BMY) has been a real pest in the world of analyzing options trading activity.  There has been a perpetual open interest alert with a monster contract volume in the DEC-2009 $30 CALLS and DEC-2009 $30 PUTS.  The culprit is tied to the company splitting off its approximately 83% holdings in Mead Johnson Nutrition Company (NYSE: MJN) and that is probably tied to this event plus an added index weighting change as Mead Johnson will be added into the S&P 500 Index.

It appears that after today that Bristol-Myers Squibb is finally going to drop off the radar of the most active contracts and open interest in options trading.  So far we have yet to see the trades roll out further on the calendar in 2010 to January, March, or June.

Bristol-Myers has seemed to be one of the routine largest open interest series out there.  The open interest that we reviewed last weekend for the DEC09 $30 CALLS was 633,140 contracts and the DEC09 $30 PUTS was 617,642 contracts.  This has gone opposite of what we expected too.  Rather than that open interest dwindling off, it has grown and was listed at 897,520 contracts in the DEC-2009 $30 CALLS and 908,246 of the DEC-2009 $30 PUTS.   On Thursday there were 95,050 contracts of the CALLS and 106,101 contracts of the PUTS.

Mead Johnson options have been active as well.  The DEC-2009 $50 CALLS traded 23,634 contracts on Thursday versus an open interest of 94,131 contracts.  The DEC-2009 $50 PUTS traded 25,571 contracts on Thursday versus an open interest of 94,256 contracts in the open interest.  The Mead Johnson shares traded over 15 million shares on Thursday versus an average volume of over 2.1 million shares, and that $41.96 share price compares to a 52-week range (less than a year actually) of $25.72 to $50.35.  Mead Johnson has also averaged over 10 million shares this week each day.

This would look like a straddle on a static basis in Bristol-Myers outside of this spin-off and index weighting change.  That 60 million shares on a fully leveraged basis last weekend (from the Bristol-Myers open interest) looks like 90 million shares worth of options volume on a fully-leveraged basis today.  Bristol-Myers traded 33.7 million shares on last Friday, yet Thursday’s trading volume was over 50 million shares and that has seen over 50 million shares on average each day this week.  In September and October this traded closer to 10 million shares.

The new 52-week trading range is $17.23 to $26.17, after the prior 52-week high of $25.97 was violated this week.  They say that active options trading generally makes stocks gravitate toward their closest most active options strike price as expiration gets closer and closer.  If so, Friday’s trading on options expiration date should have an interesting swing to it.

You can sign up for our free daily email to hear more news on key analyst calls, top day trader alerts, mergers and acquisitions, Buffett and other investment gurus, IPOs, secondary offerings, private equity, and more.

JON C. OGG

Photo of Douglas A. McIntyre
About the Author Douglas A. McIntyre →

Douglas A. McIntyre is the co-founder, chief executive officer and editor in chief of 24/7 Wall St. and 24/7 Tempo. He has held these jobs since 2006.

McIntyre has written thousands of articles for 24/7 Wall St. He is an expert on corporate finance, the automotive industry, media companies and international finance. He has edited articles on national demographics, sports, personal income and travel.

His work has been quoted or mentioned in The New York Times, The Wall Street Journal, Los Angeles Times, The Washington Post, NBC News, Time, The New Yorker, HuffPost USA Today, Business Insider, Yahoo, AOL, MarketWatch, The Atlantic, Bloomberg, New York Post, Chicago Tribune, Forbes, The Guardian and many other major publications. McIntyre has been a guest on CNBC, the BBC and television and radio stations across the country.

A magna cum laude graduate of Harvard College, McIntyre also was president of The Harvard Advocate. Founded in 1866, the Advocate is the oldest college publication in the United States.

TheStreet.com, Comps.com and Edgar Online are some of the public companies for which McIntyre served on the board of directors. He was a Vicinity Corporation board member when the company was sold to Microsoft in 2002. He served on the audit committees of some of these companies.

McIntyre has been the CEO of FutureSource, a provider of trading terminals and news to commodities and futures traders. He was president of Switchboard, the online phone directory company. He served as chairman and CEO of On2 Technologies, the video compression company that provided video compression software for Adobe’s Flash. Google bought On2 in 2009.

Featured Reads

Our top personal finance-related articles today. Your wallet will thank you later.

Continue Reading

Top Gaining Stocks

CBOE Vol: 1,568,143
PSKY Vol: 12,285,993
STX Vol: 7,378,346
ORCL Vol: 26,317,675
DDOG Vol: 6,247,779

Top Losing Stocks

LKQ
LKQ Vol: 4,367,433
CLX Vol: 13,260,523
SYK Vol: 4,519,455
MHK Vol: 1,859,865
AMGN Vol: 3,818,618